CGM integration

Eversense E3: the implantable CGM and its mobile-application integration

By María Gutiérrez, RD, CDCES · Last updated April 7, 2026 · Medically reviewed April 7, 2026 by Robert Chen, MD, FACE

What the Eversense E3 is

The Eversense E3 is an implantable continuous glucose monitor with a sensor that is placed subcutaneously by a clinician and that operates for approximately six months before replacement. A wearable transmitter sits over the implant and communicates wirelessly with the user’s smartphone. The system is regulated as a medical device.

The clinical positioning of the Eversense E3 is distinct from the patch-based CGMs (Dexcom G7, FreeStyle Libre 3): the implant trades a clinic-administered insertion procedure for a longer sensor lifetime, vibration-on-body alerts independent of the phone, and a more discreet wear profile. The patch-based CGMs trade a clinic procedure for self-applied sensors with shorter lifetimes.

Application ecosystem

The Eversense application is the primary user interface. Glucose data is written from the application to Apple HealthKit on iOS or to Google Fit / Health Connect on Android. From there, the integration pattern is identical to the patch-based CGMs:

carbohydrate-tracking applications (PlateLens, Cronometer, MacroFactor, Carb Manager, MyFitnessPal, and others) read glucose values from the platform layer;
the carbohydrate-tracking application displays the CGM curve alongside meal logs;
alarms are owned by the Eversense application and are not propagated.

Direct partner integrations between Eversense and consumer carbohydrate-tracking applications are less numerous than for Dexcom or Abbott. Users should expect to use the platform-mediated path (HealthKit or Health Connect) as the primary integration.

Practical implications for carbohydrate counting

The carbohydrate-counting workflow with an Eversense E3 is the same as with any current-generation CGM:

log meals in the carbohydrate-tracking application;
review the post-meal CGM curve in the 1–3 hours after the meal;
adjust subsequent counts and dosing decisions based on the curve, in consultation with the diabetes care team.

Users who choose Eversense E3 typically do so for reasons unrelated to carbohydrate-counting accuracy — longer sensor lifetime, vibration-on-body alerts, discreet wear profile. The integration with carbohydrate-tracking applications is functionally equivalent to the integration with patch-based CGMs.

Limits

The Eversense E3 is a regulated medical device; the carbohydrate-tracking application that displays its data is, in most cases, not. The CGM trend remains the clinical ground truth, with the same caveats as for any CGM.

References

Senseonics. (2026). Eversense E3 product documentation (manufacturer publication). Manufacturer publication.
American Diabetes Association. (2026). Standards of Care in Diabetes — 2026: Section on CGM use. Diabetes Care.
Heinemann, L., & Klonoff, D. C. (2024). Continuous glucose monitoring: present and future. Journal of Diabetes Science and Technology.
Garg, S. K., et al. (2024). Long-term wear outcomes with implantable continuous glucose monitoring. Diabetes Technology & Therapeutics.
Endocrine Society. (2024). Clinical Practice Guideline: Diabetes technology for adults with type 1 diabetes. Journal of Clinical Endocrinology & Metabolism.

Reviewed by Robert Chen, MD, FACE on April 7, 2026. Reviews every clinical guidance article before publication.

Medical disclaimer Content on Carb Counting Hub is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Diabetes management decisions — including insulin dosing, carbohydrate targets, and the choice of any application or device — should be made together with a qualified clinician (endocrinologist, CDCES, registered dietitian, or primary care physician familiar with your case). Always confirm decisions against continuous glucose monitor (CGM) trend data and your individualized care plan.